Ryan Savitz, CFO of Dianthus Therapeutics, sold 114,367 shares worth $9.49 million on March 31, 2026, exercising stock options and liquidating his entire direct common stock holdings. The sale occurred under a Rule 10b5-1 plan following the company's impressive 402% stock price gain over the past year. Savitz retains 90,399 stock options, and the company's lead candidate DNTH103 is on track for phase 3 trials mid-2026.

Dianthus Therapeutics announced the pricing of an upsized underwritten public offering of 7.3 million shares at $81.00 per share and pre-funded warrants, generating approximately $625 million in gross proceeds. The company plans to use the funds to advance clinical and preclinical development activities, commercial readiness, and general corporate purposes. The offering is expected to close on March 12, 2026.

Dianthus Therapeutics announced a conference call and webcast scheduled for March 9, 2026 to discuss interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial evaluating claseprubart for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The clinical-stage biotech company is presenting data on its investigational therapy for severe autoimmune diseases.

The generalized myasthenia gravis (gMG) market is expected to grow significantly through 2034, driven by novel immunotherapies including FABHALTA (iptacopan) from Novartis, Descartes-08 from Cartesian Therapeutics, and Claseprubart from Dianthus Therapeutics. The 7MM had approximately 205,000 prevalent gMG cases in 2024, with increasing incidence projected. These emerging therapies represent a shift toward mechanism-driven treatments targeting refractory disease and improving long-term disease control.

Dianthus Therapeutics CFO Ryan Savitz sold 20,000 shares worth $903,600 on December 4, 2025, completely eliminating his direct equity holdings. The sale was executed through exercise and immediate sale of vested stock options at a weighted average price of $45.18 per share. Despite the insider selling, the stock has retreated from its 52-week high of $45.45 but remains around $38, with analyst estimates suggesting a one-year target of $63.

Dianthus Therapeutics, a clinical-stage biotech company focused on severe autoimmune diseases, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Marino Garcia will present a corporate overview and meet with investors. The company is also advancing its lead candidate LBL-047 (DNTH212), a bifunctional fusion protein for systemic lupus erythematosus, into Phase 1 trials.

Dianthus Therapeutics reported successful Phase 2 trial results for claseprubart in generalized Myasthenia Gravis, demonstrating promising treatment effects and announcing plans for a Phase 3 trial in 2026.

Dianthus Therapeutics has entered an exclusive licensing agreement with Leads Biolabs for DNTH212, a bifunctional fusion protein targeting autoimmune diseases. The agreement involves up to $38 million in initial payments and potential milestone payments up to $962 million, with Dianthus gaining global rights outside Greater China.

Dianthus Therapeutics is conducting a public offering of 6,487,879 common stock shares and pre-funded warrants, expecting to raise approximately $251 million to support preclinical and clinical development activities.

Dianthus Therapeutics plans to raise $150 million through a public offering of common stock or pre-funded warrants, with potential additional $22.5 million from underwriters. Proceeds will support preclinical and clinical development activities.

Dianthus Therapeutics will host a conference call to discuss Phase 2 MaGic trial results for claseprubart (DNTH103) in treating generalized Myasthenia Gravis on September 8, 2025.

Dianthus Therapeutics has completed enrollment in the Phase 2 MaGic trial of its investigational drug DNTH103 for generalized Myasthenia Gravis. Top-line results are expected in September 2025. DNTH103 is also being evaluated in trials for Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy.